Search

Glaukos Corp

Closed

SectorHealthcare

153.1 0.71

Overview

Share price change

24h

Current

Min

150.02

Max

155.26

Key metrics

By Trading Economics

Income

114M

-20M

Sales

7.5M

151M

EPS

-0.18

Profit margin

-13.139

Employees

1,094

EBITDA

124M

-5.3M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+7.15% upside

Dividends

By Acuity

Next Earnings

29 Jul 2026

Market Stats

By TradingEconomics

Market Cap

2B

9.1B

Previous open

152.39

Previous close

153.1

News Sentiment

By Acuity

39%

61%

114 / 340 Healthcare

Glaukos Corp Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 Jul 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Peer Comparison

Price change

Glaukos Corp Forecast

Price Target

By TipRanks

7.15% upside

12 Months Forecast

Average 163 USD  7.15%

High 180 USD

Low 138 USD

Based on 13 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Sentiment

By Acuity

114 / 340 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat